Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $44.71 Average PT from Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have earned a consensus recommendation of “Buy” from the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $44.71.

DNTH has been the subject of a number of recent research reports. Robert W. Baird initiated coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 price objective for the company. Wedbush dropped their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, August 12th. Finally, Lifesci Capital upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DNTH. Vestal Point Capital LP bought a new stake in Dianthus Therapeutics during the 4th quarter valued at about $1,404,000. Octagon Capital Advisors LP lifted its holdings in Dianthus Therapeutics by 15.4% during the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock valued at $5,762,000 after buying an additional 74,000 shares in the last quarter. Hussman Strategic Advisors Inc. bought a new stake in Dianthus Therapeutics during the 1st quarter valued at about $630,000. Vanguard Group Inc. lifted its holdings in Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after buying an additional 384,182 shares in the last quarter. Finally, StemPoint Capital LP bought a new stake in Dianthus Therapeutics during the 1st quarter valued at about $1,304,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

DNTH opened at $27.85 on Wednesday. The stock has a market capitalization of $817.37 million, a price-to-earnings ratio of -4.78 and a beta of 1.85. The company has a fifty day moving average of $27.91 and a 200 day moving average of $26.19. Dianthus Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.01). Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. The company had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $0.63 million. On average, equities research analysts forecast that Dianthus Therapeutics will post -2.32 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.